Hybrid Nanomaterials Based on Iron Oxide Nanoparticles and Mesoporous Silica Nanoparticles: Overcoming Challenges in Current Cancer Treatments

Journal of Chemistry

Volumn 2016, Issue , 2016, Pages

  Alvarez Berrios, Merlis P ^a   Sosa Cintron, Naisha ^a   Rodriguez Lugo, Mariel ^a   Juneja, Ridhima ^b   Vivero Escoto, Juan L ^b,c  

^a INTER AMERICAN UNIVERSITY OF PUERTO RICO   (Puerto Rico)

^b UNIVERSITY OF NORTH CAROLINA AT CHARLOTTE   (United States)

^c University of North Carolina at Charlotte   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84973299826     PISSN: 20909063     EISSN: 20909071     Source Type: Journal    
DOI: 10.1155/2016/2672740     Document Type: Review

References (136)

1. Cancer Facts & Figures 2016, American Cancer Society, Atlanta, Ga, USA, 2016.
2. E. D. S. Tolentino, B. S. Centurion, L. H. C. Ferreira, A. P. de Souza, J. H. Damante, I. R. F. Rubira-Bullen, "Oral adverse effects of head and neck radiotherapy: literature reviewand suggestion of a clinical oral care guideline for irradiated patients," Journal of Applied Oral Science, vol. 19, no. 5, pp. 448-454, 2011.
3. B. A. Chabner and T. G. Roberts Jr., "Timeline: chemotherapy and the war on cancer," Nature Reviews Cancer, vol. 5, no. 1, pp. 65-72, 2005.
4. A. Nguyen, L. Ho, Y. Wan, "Chemotherapy and oncolytic virotherapy: advanced tactics in the war against cancer," Frontiers in Oncology, vol. 4, article 145, 2014.
5. C. B. Matsen and L. A. Neumayer, "Breast cancer: a review for the general surgeon," JAMA Surgery, vol. 148, no. 10, pp. 971-979, 2013.
6. M. F. Leber and T. Efferth, "Molecular principles of cancer invasion andmetastasis (review)," International Journal ofOncology, vol. 34, no. 4, pp. 881-895, 2009.
7. M. J. Sailor and J.-H. Park, "Hybrid nanoparticles for detection and treatment of cancer," Advanced Materials, vol. 24, no. 28, pp. 3779-3802, 2012.
8. J. L. Vivero-Escoto and Y.-T. Huang, "Inorganic-organic hybrid nanomaterials for therapeutic and diagnostic imaging applications," International Journal ofMolecular Sciences, vol. 12, no. 6, pp. 3888-3927, 2011.
9. X. Hao, X. Hu, C. Zhang et al., "Hybrid mesoporous silicabased drug carrier nanostructures with improved degradability by hydroxyapatite," ACS Nano, vol. 9, no. 10, pp. 9614-9625, 2015.
10. M. Torres-Lugo and C. Rinaldi, "Thermal potentiation of chemotherapy by magnetic nanoparticles," Nanomedicine, vol. 8, no. 10, pp. 1689-1707, 2013.
11. V. P. Torchilin, "Passive and active drug targeting: drug delivery to tumors as an example," Handbook of Experimental Pharmacology, no. 197, pp. 3-53, 2010.
12. I.-P. Huang, S.-P. Sun, S.-H. Cheng et al., "Enhanced chemotherapy of cancer using pH-sensitive mesoporous silica nanoparticles to antagonize P-glycoprotein-mediated drug resistance," Molecular CancerTherapeutics, vol. 10, no. 5, pp. 761-769, 2011.
13. X. Xie, F. Li, H. Zhang et al., "EpCAM aptamer-functionalized mesoporous silica nanoparticles for efficient colon cancer celltargeted drug delivery," European Journal of Pharmaceutical Sciences, vol. 83, pp. 28-35, 2016.
14. Y. Wang, Q. Zhao, N. Han et al., "Mesoporous silica nanoparticles in drug delivery and biomedical applications," Nanomedicine: Nanotechnology, Biology, Medicine, vol. 11, no. 2, pp. 313-327, 2015.
15. W. Zhang, Y. Shi, Y. Chen, J. Ye, X. Sha, X. Fang, "Multifunctional Pluronic P123/F127 mixed polymeric micelles loaded with paclitaxel for the treatment of multidrug resistant tumors," Biomaterials, vol. 32, no. 11, pp. 2894-2906, 2011.
16. M. P. Alvarez-Berŕ?os, A. Castillo, C. Rinaldi, M. Torres-Lugo, "Magnetic fluid hyperthermia enhances cytotoxicity of bortezomib in sensitive and resistant cancer cell lines," International Journal of Nanomedicine, vol. 9, pp. 145-153, 2014.
17. M. P. Alvarez-Berrios, A. Castillo, F. Merida, J. Mendez, C. Rinaldi,M. Torres-Lugo, "Enhanced proteotoxic stress: one of the contributors for hyperthermic potentiation of the proteasome inhibitor bortezomib using magnetic nanoparticles," Biomaterials Science, vol. 3, no. 2, pp. 391-400, 2015.
18. M. P. Alvarez-Berrós, A. Castillo, J. Mendéz, O. Soto,C. Rinaldi, M. Torres-Lugo, "Hyperthermic potentiation of cisplatin by magnetic nanoparticle heaters is correlated with an increase in cell membrane fluidity," International Journal of Nanomedicine, vol. 8, pp. 1003-1013, 2013.
19. B. Marincek, "Diagnostic improvement in MRI of gynecological neoplasms," Journal Belge de Radiologie, vol. 79, no. 1, pp. 13-17, 1996.
20. P. Reimer and T. Balzer, "Ferucarbotran (Resovist): a new clinically approved RES-specific contrast agent for contrastenhanced MRI of the liver: properties, clinical development, applications," European Radiology, vol. 13, no. 6, pp. 1266-1276, 2003.
21. S.-H. Hu, Y.-Y. Chen, T.-C. Liu, T.-H. Tung, D.-M. Liu, S.-Y. Chen, "Remotely nano-rupturable yolk/shell capsules for magnetically-triggered drug release," Chemical Communications, vol. 47, no. 6, pp. 1776-1778, 2011.
22. E. Amstad and E. Reimhult, "Nanoparticle actuated hollowdrug delivery vehicles," Nanomedicine, vol. 7, no. 1, pp. 145-164, 2012.
23. R. Hu, S. Ma, H. Li et al., "Effect of magnetic fluid hyperthermia on lung cancer nodules in a murine model," Oncology Letters, vol. 2, no. 6, pp. 1161-1164, 2011.
24. S. Laurent, S. Dutz, U. O. Häfeli,M. Mahmoudi, "Magnetic fluid hyperthermia: focus on superparamagnetic iron oxide nanoparticles," Advances in Colloid and Interface Science, vol. 166, no. 1-2, pp. 8-23, 2011.
25. E. H. Frei, "Magnetism and medicine," Journal of Applied Physics, vol. 40, no. 3, pp. 955-957, 1969.
26. J. Estelrich, E. Escribano, J. Queralt, M. A. Busquets, "Iron oxide nanoparticles for magnetically-guided and magneticallyresponsive drug delivery," International Journal of Molecular Sciences, vol. 16, no. 4, pp. 8070-8101, 2015.
27. A. S. Lübbe, C. Alexiou, C. Bergemann, "Clinical applications of magnetic drug targeting," Journal of Surgical Research, vol. 95, no. 2, pp. 200-206, 2001.
28. B. Polyak andG. Friedman, "Magnetic targeting for site-specific drug delivery: applications and clinical potential," Expert Opinion on Drug Delivery, vol. 6, no. 1, pp. 53-70, 2009.
29. K. J. Widder, A. E. Senyel, G.D. Scarpelli, "Magnetic microspheres: a model system of site specific drug delivery in vivo," Proceedings of the Society for Experimental Biology and Medicine, vol. 158, no. 2, pp. 141-146, 1978.
30. S. Lyer, R. Tietze, R. Jurgons et al., "Visualisation of tumour regression after local chemotherapy with magnetic nanoparticles-a pilot study," Anticancer Research, vol. 30, no. 5, pp. 1553-1557, 2010.
31. X. Thomas, M. Elhamri, Y. Chelghoum et al., "Intensive chemotherapy with mitoxantrone administered as a single injection in patients with high-risk acute myeloid leukemia: results of the EMA 2000 trial," Annals of Hematology, vol. 84, no. 6, pp. 376-382, 2005.
32. C. Alexiou, W. Arnold, R. J. Klein et al., "Locoregional cancer treatment with magnetic drug targeting," Cancer Research, vol. 60, no. 23, pp. 6641-6648, 2000.
33. C. Alexiou, R. Jurgons, R. J. Schmid et al., "Magnetic drug targeting-biodistribution of the magnetic carrier and the chemotherapeutic agentmitoxantrone after locoregional cancer treatment," Journal of Drug Targeting, vol. 11, no. 3, pp. 139-149, 2003.
34. R. Tietze, S. Lyer, S. Dürr et al., "Efficient drug-delivery usingmagnetic nanoparticles-biodistribution and therapeutic effects in tumour bearing rabbits," Nanomedicine: Nanotechnology, Biology, Medicine, vol. 9, no. 7, pp. 961-971, 2013.
35. T. M. Mekhail and M. Markman, "Paclitaxel in cancer therapy," Expert Opinion on Pharmacotherapy, vol. 3, no. 6, pp. 755-766, 2002.
36. J. Q. Zhang, Z. R. Zhang, H. Yang, Q. Y. Tan, S. R. Qin, X. L. Qiu, "Lyophilized paclitaxel magnetoliposomes as a potential drug delivery systemfor breast carcinomavia parenteral administration: in vitro and in vivo studies," Pharmaceutical Research, vol. 22, no. 4, pp. 573-583, 2005.
37. G. Beálle, R. Di Corato, J. Kolosnjaj-Tabi et al., "Ultra magnetic liposomes for MR imaging, targeting, hyperthermia," Langmuir, vol. 28, no. 32, pp. 11834-11842, 2012.
38. D. Y. Joh, L. Sun, M. Stangl et al., "Selective targeting of brain tumors with gold nanoparticle-induced radiosensitization," PLoS ONE, vol. 8, no. 4,Article ID e62425, 2013.
39. H.-L. Liu, M.-Y. Hua, H.-W. Yang et al., "Magnetic resonance monitoring of focused ultrasound/magnetic nanoparticle targeting delivery of therapeutic agents to the brain," Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 34, pp. 15205-15210, 2010.
40. B. Chertok, A. E. David, V. C. Yang, "Polyethyleneiminemodified iron oxide nanoparticles for brain tumor drug delivery using magnetic targeting and intra-carotid administration," Biomaterials, vol. 31, no. 24, pp. 6317-6324, 2010.
41. A. S. Lubbe, C. Bergemann, H. Riess et al., "Clinical experiences with magnetic drug targeting: a phase I study with 4-epidoxorubicin in 14 patients with advanced solid tumors," Cancer Research, vol. 56, no. 20, pp. 4686-4693, 1996.
42. Z. Saiyed, S. Telang,C. Ramchand, "Application ofmagnetic techniques in the field of drug discovery and biomedicine," Biomagnetic Research and Technology, vol. 1, no. 1, article 2, 2003.
43. M. W. Wilson, R. K. Kerlan Jr., N. A. Fidelman et al., "Hepatocellular carcinoma: regional therapy with a magnetic targeted carrier bound to doxorubicin in a dual MR imaging/conventional angiography suite-initial experience with four patients," Radiology, vol. 230, no. 1, pp. 287-293, 2004.
44. R. D. Issels, "Hyperthermia adds to chemotherapy," European Journal of Cancer, vol. 44, no. 17, pp. 2546-2554, 2008.
45. M. H. Falk and R. D. Issels, "Hyperthermia in oncology," International Journal of Hyperthermia, vol. 17, no. 1, pp. 1-18, 2001.
46. S. Likhitkar and A. K. Bajpai, "Magnetically controlled release of cisplatin from superparamagnetic starch nanoparticles," Carbohydrate Polymers, vol. 87, no. 1, pp. 300-308, 2012.
47. A. Rajeswaran, A. Trojan, B. Burnand, M. Giannelli, "Efficacy and side effects of cisplatin-and carboplatin-based doublet chemotherapeutic regimens versus non-platinum-based doublet chemotherapeutic regimens as first line treatment of metastatic non-small cell lung carcinoma: a systematic review of randomized controlled trials," Lung Cancer, vol. 59, no. 1, pp. 1-11, 2008.
48. M. Babincová, V. Altanerová, C. Altaner, C. Bergemann, P. Babinec, "In vitro analysis of cisplatin functionalized magnetic nanoparticles in combined cancer chemotherapy and electromagnetic hyperthermia," IEEE Transactions on NanoBioscience, vol. 7, no. 1, pp. 15-19, 2008.
49. A. J. Wagstaff, S. D. Brown, M. R. Holden et al., "Cisplatin drug delivery using gold-coated iron oxide nanoparticles for enhanced tumour targeting with external magnetic fields," Inorganica Chimica Acta, vol. 393, pp. 328-333, 2012.
50. A. Taylor, Y. Krupskaya, K. Krämer et al., "Cisplatin-loaded carbon-encapsulated iron nanoparticles and their in vitro effects in magnetic fluid hyperthermia," Carbon, vol. 48, no. 8, pp. 2327-2334, 2010.
51. J. S. Lee, H. L. Rodŕguez-Luccioni, J. Méndez et al., "Hyperthermia induced by magnetic nanoparticles improves the effectiveness of the anticancer drug cis-diamminedichloroplatinum," Journal of Nanoscience and Nanotechnology, vol. 11, no. 5, pp. 4153-4157, 2011.
52. A. A. Petryk, A. J. Giustini, R. E. Gottesman, P. A. Kaufman, P. J. Hoopes, "Magnetic nanoparticle hyperthermia enhancement of cisplatin chemotherapy cancer treatment," International Journal of Hyperthermia, vol. 29, no. 8, pp. 845-851, 2013.
53. N. A. Brusentsov, V. A. Polyanskii, Y. A. Pirogov et al., "Antitumor effects of the combination of magnetohydrodynamic thermochemotherapy and magnetic resonance tomography," Pharmaceutical Chemistry Journal, vol. 44, no. 6, pp. 291-295, 2010.
54. A. Ito, H. Saito, K. Mitobe et al., "Inhibition of heat shock protein 90 sensitizes melanoma cells to thermosensitive ferromagnetic particle-mediated hyperthermia with low Curie temperature," Cancer Science, vol. 100, no. 3, pp. 558-564, 2009.
55. E. Amstad, J. Kohlbrecher, E. Müller, T. Schweizer, M. Textor, E. Reimhult, "Triggered release from liposomes through magnetic actuation of iron oxide nanoparticle containingmembranes," Nano Letters, vol. 11, no. 4, pp. 1664-1670, 2011.
56. Y. Ren, H. Zhang, B. Chen et al., "Multifunctional magnetic Fe3O4 nanoparticles combined with chemotherapy and hyperthermia to overcome multidrug resistance," International Journal of Nanomedicine, vol. 7, pp. 2261-2269, 2012.
57. B. Piperdi, Y.-H. Ling, L. Liebes, F. Muggia, R. Perez-Soler, "Bortezomib: understanding the mechanism of action," Molecular Cancer Therapeutics, vol. 10, no. 11, pp. 2029-2030, 2011.
58. N. Neznanov, A. P. Komarov, L. Neznanova, P. Stanhope-Baker, A. V. Gudkov, "Proteotoxic stress targeted therapy (PSTT): induction of protein misfolding enhances the antitumor effect of the proteasome inhibitor bortezomib," Oncotarget, vol. 2, no. 3, pp. 209-221, 2011.
59. M. Johannsen, U. Gneveckow, L. Eckelt et al., "Clinical hyperthermia of prostate cancer using magnetic nanoparticles: presentation of a new interstitial technique," International Journal of Hyperthermia, vol. 21, no. 7, pp. 637-647, 2005.
60. M. Johannsen, B. Thiesen, P. Wust, A. Jordan, "Magnetic nanoparticle hyperthermia for prostate cancer," International Journal of Hyperthermia, vol. 26, no. 8, pp. 790-795, 2010.
61. A. Schroeder, D. A. Heller, M. M. Winslow et al., "Treating metastatic cancer with nanotechnology," Nature Reviews Cancer, vol. 12, no. 1, pp. 39-50, 2012.
62. O. L. Gobbo, K. Sjaastad, M. W. Radomski, Y. Volkov, A. Prina-Mello, "Magnetic nanoparticles in cancer theranostics," Theranostics, vol. 5, no. 11, pp. 1249-1263, 2015.
63. O. Will, S. Purkayastha, C. Chan et al., "Diagnostic precision of nanoparticle-enhanced MRI for lymph-node metastases: a meta-analysis," The Lancet Oncology, vol. 7, no. 1, pp. 52-60, 2006.
64. T. Harada, N. Tanigawa, M. Matsuki, T. Nohara, I. Narabayashi, "Evaluation of lymph node metastases of breast cancer using ultrasmall superparamagnetic iron oxide-enhancedmagnetic resonance imaging," European Journal of Radiology, vol. 63, no. 3, pp. 401-407, 2007.
65. M. G. Harisinghani, J. Barentsz, P. F. Hahn et al., "Noninvasive detection of clinically occult lymph-node metastases in prostate cancer," The New England Journal of Medicine, vol. 348, no. 25, pp. 2491-2499, 2003.
66. L. Wu, Y. Cao, C. Liao, J. Huang, F. Gao, "Diagnostic performance of USPIO-enhanced MRI for lymph-nodemetastases in different body regions: a meta-analysis," European Journal of Radiology, vol. 80, no. 2, pp. 582-589, 2011.
67. C. Leuschner, C. S. S. R. Kumar, W. Hansel, W. Soboyejo, J. Zhou, J. Hormes, "LHRH-conjugated magnetic iron oxide nanoparticles for detection of breast cancer metastases," Breast Cancer Research and Treatment, vol. 99,no. 2, pp. 163-176, 2006.
68. H. Vu-Quang, M. Muthiah, H. J. Lee et al., "Immune cellspecific delivery of beta-glucan-coated iron oxide nanoparticles for diagnosing liver metastasis by MR imaging," Carbohydrate Polymers, vol. 87, no. 2, pp. 1159-1168, 2012.
69. W. Liu, L. Nie, F. Li et al., "Folic acid conjugated magnetic iron oxide nanoparticles for nondestructive separation and detection of ovarian cancer cells from whole blood," Biomaterials Science, vol. 4, no. 1, pp. 159-166, 2016.
70. I. I. Slowing, J. L. Vivero-Escoto, C.-W. Wu, V. S.-Y. Lin, "Mesoporous silica nanoparticles as controlled release drug delivery and gene transfection carriers," Advanced Drug Delivery Reviews, vol. 60, no. 11, pp. 1278-1288, 2008.
71. Y. Kuthati, P.-J. Sung, C.-F. Weng, C.-Y. Mou, C.-H. Lee, "Functionalization of mesoporous silica nanoparticles for targeting, biocompatibility, combined cancer therapies and theragnosis," Journal of Nanoscience and Nanotechnology, vol. 13, no. 4, pp. 2399-2430, 2013.
72. Y. Chen,H. Chen, S. Zhang et al., "Multifunctionalmesoporous nanoellipsoids for biological bimodal imaging andmagnetically targeted delivery of anticancer drugs," Advanced Functional Materials, vol. 21, no. 2, pp. 270-278, 2011.
73. W. Zhao, H. Chen, Y. Li, A. Li,M. Lang, J. Shi, "Uniform rattle-type hollow magnetic mesoporous spheres as drug delivery carriers and their sustained-release property," Advanced Functional Materials, vol. 18, no. 18, pp. 2780-2788, 2008.
74. H. Tu, Y. Lin, H. Lin et al., "In vitro studies of functionalized mesoporous silica nanoparticles for photodynamic therapy," Advanced Materials, vol. 21, no. 2, pp. 172-177, 2009.
75. J. E. Lee, N. Lee, H. Kim et al., "Uniform mesoporous dyedoped silica nanoparticles decorated with multiple magnetite nanocrystals for simultaneous enhanced magnetic resonance imaging, fluorescence imaging, drug delivery," Journal of the American Chemical Society, vol. 132, no. 2, pp. 552-557, 2010.
76. C. Caltagirone, A. Bettoschi, A. Garau, R. Montis, "Silicabased nanoparticles: a versatile tool for the development of efficient imaging agents," Chemical Society Reviews, vol. 44, no. 14, pp. 4645-4671, 2015.
77. J. L. Vivero-Escoto, R. C. Huxford-Phillips,W. Lin, "Silicabased nanoprobes for biomedical imaging and theranostic applications," Chemical Society Reviews, vol. 41, no. 7, pp. 2673-2685, 2012.
78. N.-T. Chen, S.-H. Cheng, J. S. Souris, C.-T. Chen, C.-Y. Mou, L.-W. Lo, "Theranostic applications of mesoporous silica nanoparticles and their organic/inorganic hybrids," Journal of Materials Chemistry B, vol. 1, no. 25, pp. 3128-3135, 2013.
79. J. L. Vivero-Escoto, I. I. Slowing, V. S.-Y. Lin, B. G. Trewyn, "Mesoporous silica nanoparticles for intracellular controlled drug delivery," Small, vol. 6, no. 18, pp. 1952-1967, 2010.
80. L. Kelland, "The resurgence of platinum-based cancer chemotherapy," Nature Reviews Cancer, vol. 7, no. 8, pp. 573-584, 2007.
81. M. Markman, "Toxicities of the platinumantineoplastic agents," Expert Opinion on Drug Safety, vol. 2, no. 6, pp. 597-607, 2003.
82. J. Reedijk, "New clues for platinum antitumor chemistry: kinetically controlledmetal binding to DNA," Proceedings of the NationalAcademy of Sciences of theUnited States ofAmerica, vol. 100, no. 7, pp. 3611-3616, 2003.
83. P. R. Brock, K. R. Knight, D. R. Freyer et al., "Platinum-induced ototoxicity in children: a consensus review on mechanisms, predisposition, protection, including a new International Society of Pediatric Oncology Boston ototoxicity scale," Journal of Clinical Oncology, vol. 30, no. 19, pp. 2408-2417, 2012.
84. N. Bardeesy and R. A. DePinho, "Pancreatic cancer biology and genetics," Nature Reviews Cancer, vol. 2, no. 12, pp. 897-909, 2002.
85. A. Stathis and M. J. Moore, "Advanced pancreatic carcinoma: current treatment and future challenges," Nature Reviews Clinical Oncology, vol. 7, no. 3, pp. 163-172, 2010.
86. M. K. Gurka, D. Pender, P. Chuong et al., "Identification of pancreatic tumors in vivo with ligand-targeted, pH responsive mesoporous silica nanoparticles by multispectral optoacoustic tomography," Journal of Controlled Release, 2016.
87. Q. Zhang, K. G. Neoh, L. Xu et al., "Functionalized mesoporous silica nanoparticles with mucoadhesive and sustained drug release properties for potential bladder cancer therapy," Langmuir, vol. 30, no. 21, pp. 6151-6161, 2014.
88. S. Jambhrunkar, S. Karmakar, A. Popat, M. Yu, C. Yu, "Mesoporous silica nanoparticles enhance the cytotoxicity of curcumin," RSC Advances, vol. 4, no. 2, pp. 709-712, 2014.
89. E. Niemelä, D. Desai, Y. Nkizinkiko, J. E. Eriksson, J. M. Rosenholm, "Sugar-decorated mesoporous silica nanoparticles as delivery vehicles for the poorly soluble drug celastrol enables targeted induction of apoptosis in cancer cells," European Journal of Pharmaceutics and Biopharmaceutics, vol. 96, pp. 11-21, 2015.
90. K. Wang, H. Yao, Y. Meng, Y. Wang, X. Yan,R. Huang, "Specific aptamer-conjugated mesoporous silica-carbon nanoparticles for HER2-targeted chemo-photothermal combined therapy," Acta Biomaterialia, vol. 16, no. 1, pp. 196-205, 2015.
91. X. Hu, M. Wang, F. Miao, J. Ma, H. Shen, N. Jia, "Regulation of multifunctional mesoporous core-shell nanoparticles with luminescence and magnetic properties for biomedical applications," Journal ofMaterials Chemistry B, vol. 2, no. 16, pp. 2265-2275, 2014.
92. Y. Chen, K. Ai, J. Liu, G. Sun, Q. Yin, L. Lu, "Multifunctional envelope-type mesoporous silica nanoparticles for pHresponsive drug delivery and magnetic resonance imaging," Biomaterials, vol. 60, pp. 111-120, 2015.
93. M.-H. Chan and H.-M. Lin, "Preparation and identification of multifunctional mesoporous silica nanoparticles for in vitro and in vivo dual-mode imaging, theranostics, targeted tracking," Biomaterials, vol. 46, pp. 149-158, 2015.
94. K. O. Alfarouk, C.-M. Stock, S. Taylor et al., "Resistance to cancer chemotherapy: failure in drug response from ADME to P-gp," Cancer Cell International, vol. 15, article 71, 2015.
95. S. Chen, Z. Wang, Y. Huang et al., "Ginseng and anticancer drug combination to improve cancer chemotherapy: a critical review," Evidence-Based Complementary and Alternative Medicine, vol. 2014, Article ID 168940, 13 pages, 2014.
96. Y. Gao, Y. Chen, X. Ji et al., "Controlled intracellular release of doxorubicin in multidrug-resistant cancer cells by tuning the shell-pore sizes of mesoporous silica nanoparticles," ACS Nano, vol. 5, no. 12, pp. 9788-9798, 2011.
97. Y. Chen, Q. Yin, X. Ji et al., "Manganese oxide-basedmultifunctionalized mesoporous silica nanoparticles for pH-responsive MRI, ultrasonography and circumvention of MDR in cancer cells," Biomaterials, vol. 33, no. 29, pp. 7126-7137, 2012.
98. W. C. Zamboni, V. Torchilin, A. K. Patri et al., "Best practices in cancer nanotechnology: perspective fromNCI nanotechnology alliance," Clinical Cancer Research, vol. 18, no. 12, pp. 3229-3241, 2012.
99. B. Li, H. Xu, Z. Li et al., "Bypassing multidrug resistance in human breast cancer cells with lipid/polymer particle assemblies," International Journal of Nanomedicine, vol. 7, pp. 187-197, 2012.
100. W. Jiang, B. Y. S. Kim, J. T. Rutka, W. C. W. Chan, "Nanoparticle-mediated cellular response is size-dependent," Nature Nanotechnology, vol. 3, no. 3, pp. 145-150, 2008.
101. W. Punfa, S. Yodkeeree, P. Pitchakarn, C. Ampasavate, P. Limtrakul, "Enhancement of cellular uptake and cytotoxicity of curcumin-loaded PLGA nanoparticles by conjugation with anti-P-glycoprotein in drug resistance cancer cells," Acta Pharmacologica Sinica, vol. 33, no. 6, pp. 823-831, 2012.
102. A. S. Goncąlves, A. S. Macedo, E. B. Souto, "Therapeutic nanosystems for oncology nanomedicine," Clinical and Translational Oncology, vol. 14, no. 12, pp. 883-890, 2012.
103. T. Nabekura, "Overcoming multidrug resistance in human cancer cells by natural compounds," Toxins, vol. 2, no. 6, pp. 1207-1224, 2010.
104. A. M. Chen, M. Zhang, D. Wei et al., "Co-delivery of doxorubicin and Bcl-2 siRNA by mesoporous silica nanoparticles enhances the efficacy of chemotherapy in multidrug-resistant cancer cells," Small, vol. 5, no. 23, pp. 2673-2677, 2009.
105. C. E. Ashley, E. C. Carnes, G. K. Phillips et al., "The targeted delivery of multicomponent cargos to cancer cells by nanoporous particle-supported lipid bilayers," Nature Materials, vol. 10, no. 6, p. 476, 2011, Erratum to document cited in CA155:021668.
106. A.M. Calcagno, C. D. Salcido, J.-P. Gillet et al., "Prolonged drug selection of breast cancer cells and enrichment of cancer stem cell characteristics," Journal of the National Cancer Institute, vol. 102, no. 21, pp. 1637-1652, 2010.
107. J. W. Cain, R. S. Hauptschein, J. K. Stewart, T. Bagci, G. G. Sahagian, D. G. Jay, "Identification of CD44 as a surface biomarker for drug resistance by surface proteome signature technology," Molecular Cancer Research, vol. 9, no. 5, pp. 637-647, 2011.
108. D. Wang, J. Huang, X. Wang et al., "The eradication of breast cancer cells and stem cells by 8-hydroxyquinolineloaded hyaluronan modified mesoporous silica nanoparticlesupported lipid bilayers containing docetaxel," Biomaterials, vol. 34, no. 31, pp. 7662-7673, 2013.
109. X. Wang, Y. Liu, S. Wang et al., "CD44-engineered mesoporous silica nanoparticles for overcoming multidrug resistance in breast cancer," Applied Surface Science, vol. 332, pp. 308-317, 2015.
110. Q. Yin, J. Shen, Z. Zhang, H. Yu, Y. Li, "Reversal of multidrug resistance by stimuli-responsive drug delivery systems for therapy of tumor," Advanced Drug Delivery Reviews, vol. 65, no. 13-14, pp. 1699-1715, 2013.
111. Q. He, Y. Gao, L. Zhang et al., "A pH-responsive mesoporous silica nanoparticles-based multi-drug delivery system for overcoming multi-drug resistance," Biomaterials, vol. 32, no. 30, pp. 7711-7720, 2011.
112. C.-H. Lee, S. Cheng, I. Huang et al., "Intracellular pHresponsive mesoporous silica nanoparticles for the controlled release of anticancer chemotherapeutics," Angewandte Chemie-International Edition, vol. 49, no. 44, pp. 8214-8219, 2010.
113. X. Zhang, F. Li, S. Guo et al., "Biofunctionalized polymerlipid supported mesoporous silica nanoparticles for release of chemotherapeutics in multidrug resistant cancer cells," Biomaterials, vol. 35, no. 11, pp. 3650-3665, 2014.
114. L. Xiang, P. Su, S. Xia et al., "ABCG2 is associated with HER-2 expression, lymph node metastasis and clinical stage in breast invasive ductal carcinoma," Diagnostic Pathology, vol. 6, article 90, 2011.
115. D. Damiani, M. Tiribelli, A. Michelutti et al., "Fludarabinebased induction therapy does not overcome the negative effect of ABCG2 (BCRP) over-expression in adult acute myeloid leukemia patients," Leukemia Research, vol. 34, no. 7, pp. 942-945, 2010.
116. S. H. Lee, H. Kim, J.-H. Hwang et al., "Breast cancer resistance protein expression is associated with early recurrence and decreased survival in resectable pancreatic cancer patients," Pathology International, vol. 62, no. 3, pp. 167-175, 2012.
117. C. H. C. Sukowati, N. Rosso, D. Pascut et al., "Gene and functional up-regulation of the BCRP/ABCG2 transporter in hepatocellular carcinoma," BMC Gastroenterology, vol. 12, article 160, 2012.
118. Y. Zhao, D. Y. Alakhova, J. O. Kim, T. K. Bronich, A. V. Kabanov, "A simple way to enhance Doxil-therapy: drug release from liposomes at the tumor site by amphiphilic block copolymer," Journal of Controlled Release, vol. 168, no. 1, pp. 61-69, 2013.
119. E. V. Batrakova, S. Li, A.M. Brynskikh et al., "Effects of pluronic and doxorubicin on drug uptake, cellularmetabolism, apoptosis and tumor inhibition in animal models of MDR cancers," Journal of Controlled Release, vol. 143, no. 3, pp. 290-301, 2010.
120. T. Yamagata, M. Morishita, H. Kusuhara, K. Takayama, H. Benameur, Y. Sugiyama, "Characterization of the inhibition of breast cancer resistance protein-mediated efflux of mitoxantrone by pharmaceutical excipients," International Journal of Pharmaceutics, vol. 370, no. 1-2, pp. 216-219, 2009.
121. L. Pan, J. Liu, Q. He, L. Wang, J. Shi, "Overcoming multidrug resistance of cancer cells by direct intranuclear drug delivery using TAT-conjugated mesoporous silica nanoparticles," Biomaterials, vol. 34, no. 11, pp. 2719-2730, 2013.
122. L. Jia, Z. Li, J. Shen et al., "Multifunctional mesoporous silica nanoparticles mediated co-delivery of paclitaxel and tetrandrine for overcoming multidrug resistance," International Journal of Pharmaceutics, vol. 489, no. 1-2, pp. 318-330, 2015.
123. N. Han, Q. Zhao, L. Wan et al., "Hybrid lipid-capped mesoporous silica for stimuli-responsive drug release and overcomingmultidrug resistance," ACS AppliedMaterials and Interfaces, vol. 7, no. 5, pp. 3342-3351, 2015.
124. D. Spano, C. Heck, P. deAntonellis,G. Christofori, M. Zollo, "Molecular networks that regulate cancer metastasis," Seminars in Cancer Biology, vol. 22, no. 3, pp. 234-249, 2012.
125. Q. He, S. Guo, Z. Qian, X. Chen, "Development of individualized anti-metastasis strategies by engineering nanomedicines," Chemical Society Reviews, vol. 44, no. 17, pp. 6258-6286, 2015.
126. Y. Chen, P. Xu, H. Chen et al., "Colloidal HPMOnanoparticles: silica-etching chemistry tailoring, topological transformation, nano-biomedical applications," Advanced Materials, vol. 25, no. 22, pp. 3100-3105, 2013.
127. Y. Chen,H. Gu, D. S.-Z. Zhang, F. Li, T. Liu,W. Xia, "Highly effective inhibition of lung cancer growth and metastasis by systemic delivery of siRNA via multimodal mesoporous silicabased nanocarrier," Biomaterials, vol. 35, no. 38, pp. 10058-10069, 2014.
128. M. Egeblad and Z. Werb, "New functions for the matrix metalloproteinases in cancer progression," Nature Reviews Cancer, vol. 2, no. 3, pp. 161-174, 2002.
129. S. H. van Rijt, D. A. Bölükbas, C. Argyo et al., "Protease-mediated release of chemotherapeutics from mesoporous silica nanoparticles to ex vivo human and mouse lung tumors," ACS Nano, vol. 9, no. 3, pp. 2377-2389, 2015.
130. R. Roy, J. Yang, M. A. Moses, "Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer," Journal of Clinical Oncology, vol. 27, no. 31, pp. 5287-5297, 2009.
131. D. Castanotto and J. J. Rossi, "The promises and pitfalls of RNAinterference-based therapeutics," Nature, vol. 457, no. 7228, pp. 426-433, 2009.
132. Y. Chen, X. Zhu, X. Zhang, B. Liu, L. Huang, "Nanoparticles modified with tumor-targeting scFv deliver siRNA and miRNA for cancer therapy," MolecularTherapy, vol. 18, no. 9, pp. 1650-1656, 2010.
133. M. Potente, H. Gerhardt, P. Carmeliet, "Basic and therapeutic aspects of angiogenesis," Cell, vol. 146, no. 6, pp. 873-887, 2011.
134. Y. Ohta, Y. Endo, M. Tanaka et al., "Significance of vascular endothelial growth factor messenger RNA expression in primary lung cancer," Clinical Cancer Research, vol. 2, no. 8, pp. 1411-1416, 1996.
135. D. Bumcrot, M. Manoharan, V. Koteliansky, D. W. Y. Sah, "RNAi therapeutics: a potential new class of pharmaceutical drugs," Nature Chemical Biology, vol. 2, no. 12, pp. 711-719, 2006.
136. X. Liu, A. Situ,Y. Kang et al., "Irinotecan delivery by lipid-coated mesoporous silica nanoparticles shows improved efficacy and safety over liposomes for pancreatic cancer," ACS Nano, vol. 10, no. 2, pp. 2702-2715, 2016.